JP2017524366A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524366A5
JP2017524366A5 JP2017507848A JP2017507848A JP2017524366A5 JP 2017524366 A5 JP2017524366 A5 JP 2017524366A5 JP 2017507848 A JP2017507848 A JP 2017507848A JP 2017507848 A JP2017507848 A JP 2017507848A JP 2017524366 A5 JP2017524366 A5 JP 2017524366A5
Authority
JP
Japan
Prior art keywords
protein
factor
furin
transformed
transformed cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017507848A
Other languages
English (en)
Japanese (ja)
Other versions
JP6793114B2 (ja
JP2017524366A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/044883 external-priority patent/WO2016025615A1/en
Publication of JP2017524366A publication Critical patent/JP2017524366A/ja
Publication of JP2017524366A5 publication Critical patent/JP2017524366A5/ja
Application granted granted Critical
Publication of JP6793114B2 publication Critical patent/JP6793114B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017507848A 2014-08-12 2015-08-12 フューリンを分泌する哺乳動物の発現系における、完全に処理され機能的な第x因子の産生 Active JP6793114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036438P 2014-08-12 2014-08-12
US62/036,438 2014-08-12
PCT/US2015/044883 WO2016025615A1 (en) 2014-08-12 2015-08-12 Production of fully processed and functional factor x in a furin-secreting mammalian expression system

Publications (3)

Publication Number Publication Date
JP2017524366A JP2017524366A (ja) 2017-08-31
JP2017524366A5 true JP2017524366A5 (enExample) 2018-09-27
JP6793114B2 JP6793114B2 (ja) 2020-12-09

Family

ID=54035298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017507848A Active JP6793114B2 (ja) 2014-08-12 2015-08-12 フューリンを分泌する哺乳動物の発現系における、完全に処理され機能的な第x因子の産生

Country Status (14)

Country Link
US (1) US9873892B2 (enExample)
EP (1) EP3180427B1 (enExample)
JP (1) JP6793114B2 (enExample)
CN (1) CN107002041B (enExample)
AR (1) AR102048A1 (enExample)
AU (1) AU2015301726B2 (enExample)
CA (1) CA2958056C (enExample)
EA (1) EA035444B1 (enExample)
ES (1) ES2742724T3 (enExample)
IL (1) IL250530B (enExample)
MX (1) MX377236B (enExample)
NZ (1) NZ729729A (enExample)
TW (1) TWI666319B (enExample)
WO (1) WO2016025615A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US11299533B2 (en) 2017-06-23 2022-04-12 Takeda Pharmaceutical Company Limited Purification of factor VIII subspecies
WO2020257942A1 (en) * 2019-06-28 2020-12-30 Peel Sean A F A method for increasing yields and the specific activity of certain recombinant proteins in mammalian cells by co-expressing full-length furin
GB202018320D0 (en) * 2020-11-20 2021-01-06 Univ Newcastle Methods of producing recombinant complement proteins
CN115298204B (zh) * 2022-01-25 2023-04-25 青岛万明赛伯药业有限公司 proNGF突变体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2109336T3 (es) 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
JPH09295945A (ja) * 1996-04-30 1997-11-18 Hoechst Yakuhin Kogyo Kk 成熟型骨誘導因子の製造方法
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
EP2292657A1 (en) 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
JP2007502623A (ja) * 2003-05-09 2007-02-15 リサーチ ディベロップメント ファウンデーション 膜タンパク質におけるフリンプロテアーゼ開裂部位の挿入およびその使用法
SI1969127T2 (sl) * 2005-12-21 2017-10-30 Cnj Holdings, Inc Metoda pridobivanja biološko aktivnih proteinov, odvisnih od vitamina K, z rekombinantnimi metodami
PL2152735T3 (pl) * 2007-05-18 2015-08-31 Baxalta Inc Sposób wytwarzania dojrzałego VWF z propeptydu
EP3521422B1 (en) * 2007-12-31 2021-10-06 Takeda Pharmaceutical Company Limited Substantially animal protein-free recombinat furin and methods for producing same
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
JP5797837B2 (ja) * 2011-06-02 2015-10-21 バクスター、インターナショナル、インコーポレイテッド 組換えフューリン製剤

Similar Documents

Publication Publication Date Title
PH12020551039A1 (en) Non-viral dna vectors and uses thereof for antibody and fusion protein production
IL259120A (en) Her2-targeted antigen chimeric receptors2
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
JP2017524366A5 (enExample)
MX2023009050A (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas.
MX2018011384A (es) Arn de replicacion en trans.
WO2016092550A3 (en) Methods of producing long acting ctp-modified polypeptides
NZ751946A (en) Rna-guided nucleic acid modifying enzymes and methods of use thereof
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
MX384960B (es) Cultivo celular metabolicamente optimizado
MY205245A (en) Scalable method for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
IL292650B1 (en) COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Ra2
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
JP2010518833A5 (enExample)
MX366910B (es) Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
RU2014148136A (ru) Композиции т-клеток с недостаточностью рецепторов т-клеток
JP2016105737A5 (enExample)
ATE481483T1 (de) Verfahren zur herstellung eines rekombinanten polyklonalen proteins
IN2014DN03419A (enExample)
WO2011091350A3 (en) Methods & compositions for improving protein production
JP2020509751A5 (enExample)
WO2020047467A3 (en) Cardiac cell reprogramming with myocardin and ascl1
WO2014097113A3 (en) Production of therapeutic proteins in genetically modified mammalian cells
JP2016501515A5 (enExample)
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы